2020
Exenatide extended release in patients with type 1 diabetes with and without residual insulin production
Herold KC, Reynolds J, Dziura J, Baidal D, Gaglia J, Gitelman SE, Gottlieb PA, Marks J, Philipson LH, Pop‐Busui R, Weinstock RS. Exenatide extended release in patients with type 1 diabetes with and without residual insulin production. Diabetes Obesity And Metabolism 2020, 22: 2045-2054. PMID: 32573927, PMCID: PMC8009602, DOI: 10.1111/dom.14121.Peer-Reviewed Original ResearchConceptsExenatide extended releaseResidual insulin productionBeta-cell functionType 1 diabetesC-peptidePlacebo groupPrimary outcomeWeek 12ER groupInsulin productionDetectable C-peptide levelsResidual beta-cell functionGLP-1 receptor agonistsRandomized placebo-controlled trialExtended releaseTotal insulin doseMean HbA1c levelPlacebo-controlled trialC-peptide levelsDetectable levelsCell functionShort-term improvementHbA1c levelsStudy drugAdverse events
2018
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis
Perdigoto AL, Preston-Hurlburt P, Clark P, Long SA, Linsley PS, Harris KM, Gitelman SE, Greenbaum CJ, Gottlieb PA, Hagopian W, Woodwyk A, Dziura J, Herold KC. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. Diabetologia 2018, 62: 655-664. PMID: 30569273, PMCID: PMC6402971, DOI: 10.1007/s00125-018-4786-9.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntibodies, Monoclonal, HumanizedArea Under CurveAutoimmunityCD3 ComplexCD8-Positive T-LymphocytesChildC-PeptideCytokinesDiabetes Mellitus, Type 1FemaleFollow-Up StudiesHumansHypoglycemic AgentsInsulinIslets of LangerhansMaleRandomized Controlled Trials as TopicRemission InductionTreatment OutcomeYoung AdultConceptsC-peptide responseType 1 diabetesMixed meal tolerance testDetectable C-peptideC-peptideInsulin useTolerance testT cellsControl groupNew-onset type 1 diabetesPeripheral blood mononuclear cellsConclusions/interpretationThese findingsAnti-CD3 monoclonal antibodyDaily insulin useBlood mononuclear cellsDiagnosis of diabetesSuccessful immune therapiesOriginal control groupCell death proteinAnergic CD8ResultsFifty-sixImmune therapyInterpretationThese findingsMononuclear cellsCytokine release
2008
Primary Defects in β-Cell Function Further Exacerbated by Worsening of Insulin Resistance Mark the Development of Impaired Glucose Tolerance in Obese Adolescents
Cali AM, Man CD, Cobelli C, Dziura J, Seyal A, Shaw M, Allen K, Chen S, Caprio S. Primary Defects in β-Cell Function Further Exacerbated by Worsening of Insulin Resistance Mark the Development of Impaired Glucose Tolerance in Obese Adolescents. Diabetes Care 2008, 32: 456-461. PMID: 19106382, PMCID: PMC2646028, DOI: 10.2337/dc08-1274.Peer-Reviewed Original ResearchConceptsImpaired glucose toleranceNormal glucose toleranceBeta-cell functionBeta-cell responsivityObese adolescentsGlucose toleranceDisposition indexOral glucose tolerance testProgressive declinePre-diabetic stateGlucose tolerance testBMI z-scorePrimary defectGlucose intoleranceGlucose areaTolerance testPlasma glucoseInsulin sensitivityC-peptideInsulin secretionNonprogressorsZ-scoreNatural historyProgressorsPercent fat
2007
High Visceral and Low Abdominal Subcutaneous Fat Stores in the Obese Adolescent A Determinant of an Adverse Metabolic Phenotype
Taksali SE, Caprio S, Dziura J, Dufour S, Calí A, Goodman TR, Papademetris X, Burgert TS, Pierpont BM, Savoye M, Shaw M, Seyal AA, Weiss R. High Visceral and Low Abdominal Subcutaneous Fat Stores in the Obese Adolescent A Determinant of an Adverse Metabolic Phenotype. Diabetes 2007, 57: 367-371. PMID: 17977954, DOI: 10.2337/db07-0932.Peer-Reviewed Original ResearchConceptsMetabolic syndromeObese adolescentsInsulin resistanceVisceral fatSubcutaneous fatAdverse metabolic phenotypeC-reactive proteinSevere metabolic complicationsAbdominal subcutaneous fatBMI z-scoreProton magnetic resonance spectroscopyMulti-ethnic cohortFat-free massSubcutaneous fat depotsMagnetic resonance imagingSubcutaneous fat storesMetabolic complicationsTotal adiponectinHepatic fatLiver fatTriglyceride levelsInterleukin-6Visceral depotsOdds ratioC-peptide